Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Subscribe To Our Newsletter & Stay Updated